Castle Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL), a healthcare diagnostics company, announced its participation in three upcoming investor conferences in September 2025. The company will present at Baird's 2025 Global Healthcare Conference on September 10 at 10:15 a.m. Eastern time, with a live webcast available on their investor relations website.

Additionally, Castle's management will be available for one-on-one meetings during the Wells Fargo Healthcare Conference on September 4 and the Lake Street Best Ideas Growth Conference on September 11. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets.

FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird’s 2025 Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 10:15 a.m. Eastern time.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.

Castle will also be available for one-on-one investor meetings during the Wells Fargo 20^th Annual Healthcare Conference on Sept. 4, 2025, and the 9^th Annual Lake Street Best Ideas Growth (BIG9) Conference on Sept. 11, 2025. Meetings may be requested exclusively through Wells Fargo and Lake Street Capital Markets.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:
Allison Marshall
amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

FAQ

When is Castle Biosciences (CSTL) presenting at Baird's 2025 Global Healthcare Conference?

Castle Biosciences will present on Wednesday, September 10, 2025, at 10:15 a.m. Eastern time.

How can investors access Castle Biosciences' (CSTL) presentation at the Baird conference?

Investors can access the live audio webcast of the presentation through Castle Biosciences' website at ir.castlebiosciences.com/events-presentations/. A replay will be available after the broadcast.

Which investor conferences will Castle Biosciences (CSTL) attend in September 2025?

Castle Biosciences will attend three conferences: Wells Fargo Healthcare Conference (Sept. 4), Baird's Global Healthcare Conference (Sept. 10), and Lake Street Best Ideas Growth Conference (Sept. 11).

How can investors schedule one-on-one meetings with Castle Biosciences (CSTL) management?

One-on-one meetings can be requested exclusively through Wells Fargo for the Wells Fargo Healthcare Conference and through Lake Street Capital Markets for the Lake Street conference.